Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)
ConclusionWe defined the maximum tolerated dose and the recommended dose for combination therapy with gemcitabine/nab-paclitaxel/S-1 as dose level-1. Considering the observed response rate, further studies are warranted in order to determine the efficacy of this regimen (UMIN-CTR 000030007). (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 24, 2020 Category: Cancer & Oncology Source Type: research

Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin
ConclusionThe dUr level before and during administration of 5-FU and arfolitixorin was predictive for toxicity and early clinical response and could be a potential surrogate marker for thymidylate synthase inhibition in patients with mCRC.Trial registrationNCT02244632, first posted on ClinicalTrials.gov on September 19, 2014 (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 24, 2020 Category: Cancer & Oncology Source Type: research

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors
ConclusionsCombined onalespib and AT7519 is tolerable, though below monotherapy RP2D. Promising preliminary clinical activity was seen. Further benefit may be seen with the incorporation of molecular signature pre-selection. Further biomarker development will require the assessment of the on-target impact on relevant client proteins in tumor tissue. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 23, 2020 Category: Cancer & Oncology Source Type: research

Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children ’s Oncology Group phase 1 consortium study (ADVL1212)
ConclusionsThe RP2D of crizotinib FCs in combination with cyclophosphamide and topotecan was 215  mg/m2/dose BID. The oral solution of crizotinib was not palatable in this patient population. Crizotinib cMS was palatable; however, patients experienced increased toxicity that was not explained by the relative bioavailability or exposure and warrants further investigation.Clinical trial registryThe trial is registered as NCT01606878 at Clinicaltrials.gov. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 23, 2020 Category: Cancer & Oncology Source Type: research

Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma
ConclusionMaintaining Ctrough median above 42.68  ng/mL was crucial for achieving the ORR in patients with HCC. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 23, 2020 Category: Cancer & Oncology Source Type: research

The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo
ConclusionsP26, as a novel TIM3-binding peptide, has the ideal bioactivity connecting to TIM3 and the potential prospect of application in immunotherapy as an alternative or adjuvant to existing agents. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 21, 2020 Category: Cancer & Oncology Source Type: research

Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal ® ) in glioma patients in China
ConclusionIt can be concluded that 20-mg and 100-mg capsules of TOZ309 are bioequivalent to Temodal® capsules of the same strength under fasting conditions.Trial registrationhttps://www.chinadrugtrials.org.cn/index.html, CTR2017 0122. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 21, 2020 Category: Cancer & Oncology Source Type: research

Combination of levetiracetam and IFN- α increased temozolomide efficacy in MGMT-positive glioma
ConclusionsThe combination use of LEV and IFN- α could be an optimal method to overcome TMZ resistance through obvious MGMT inhibition in MGMT-positive glioma. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 19, 2020 Category: Cancer & Oncology Source Type: research

All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma
ConclusionAll-oral DEVEC showed an encouraging activity and acceptable toxicity. This schedule deserves further studies in elderly PTCL also for assessing combinations with targeted drugs. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 18, 2020 Category: Cancer & Oncology Source Type: research

Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer
ConclusionsThis study demonstrated the valuable roles of circulating exosomal miR-1246 and miR-155 in distinguishing trastuzumab resistant from sensitive patients. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 17, 2020 Category: Cancer & Oncology Source Type: research

Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients
ConclusionOur results might provide guidance in cases with heavily pre-treated patients, where alternatives are limited. Carboplatin and bevacizumab treatment should be weighed against best supportive care, current non-platinum therapies and experimental treatment. cfDNA seems to offer prognostic insight. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 16, 2020 Category: Cancer & Oncology Source Type: research

Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors
ConclusionWe demonstrated that ALL survivors have higher levels of urine NGAL, NGAL/cr. and uKIM-1/cr. ratio as compared to the control group. Further long-term follow-up studies are necessary to assess the significance of the NGAL and KIM-1 and their relationship to kidney damage after anticancer treatment in childhood. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 14, 2020 Category: Cancer & Oncology Source Type: research

The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis
ConclusionsSerum CA19 ‑9 is valuable in determining the effect of neoadjuvant treatment in patients with PC. Post-neoadjuvant CA19-9 response >  50% or CA19-9 normalization was related to a more promising overall survival, suggesting that optimal CA19-9 response may be a suitable prognostic index to guide treatment decisions. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 12, 2020 Category: Cancer & Oncology Source Type: research

Mass balance, metabolic disposition, and pharmacokinetics of [ 14 C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects followin g oral administration
ConclusionIt was well tolerated in the six healthy male subjects following a single oral administration of 200  mg/100 μCi dose of ensartinib. Besides unchanged ensartinib, metabolite of M465 was the predominant circulating drug-related component. The drug was primarily eliminated in feces.Clinical trial registrationClinicalTrials.gov NCT03804541. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 12, 2020 Category: Cancer & Oncology Source Type: research

Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid
ConclusionCyclooxygenase inhibition by non-steroidal anti-inflammatory drugs represents a therapeutic opportunity to augment the modest anti-CRC activity of EPA. However, intra-tumoral COX inhibition is likely to be critical for this drug-nutrient interaction and careful tissue pharmacodynamic profiling is required in subsequent pre-clinical and human studies. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - October 11, 2020 Category: Cancer & Oncology Source Type: research